Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Total Current Liabilities (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Total Current Liabilities for 13 consecutive years, with $252.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Current Liabilities fell 2.6% year-over-year to $252.5 million, compared with a TTM value of $252.5 million through Sep 2025, down 2.6%, and an annual FY2024 reading of $247.0 million, up 26.52% over the prior year.
  • Total Current Liabilities was $252.5 million for Q3 2025 at Tandem Diabetes Care, roughly flat from $251.7 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $288.2 million in Q1 2025 and bottomed at $103.4 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $186.0 million, with a median of $174.7 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities fell 4.89% in 2021, then soared 49.34% in 2025.
  • Year by year, Total Current Liabilities stood at $131.9 million in 2021, then increased by 25.36% to $165.3 million in 2022, then increased by 18.13% to $195.3 million in 2023, then increased by 26.52% to $247.0 million in 2024, then rose by 2.22% to $252.5 million in 2025.
  • Business Quant data shows Total Current Liabilities for TNDM at $252.5 million in Q3 2025, $251.7 million in Q2 2025, and $288.2 million in Q1 2025.